Rana McKay: Integration of HSD3B1 into germline testing and clinical trials in Prostate Cancer
Rana McKay, Associate Professor of Medicine at UC San Diego, shared a post on X:
“Data support the integration of HSD3B1 into germline testing and clinical trials in PC. Highly prevalent adrenal permissive SNP impacts outcomes and ADT sensitivity. Amazing work by Nima Sharifi in this field.”
HSD3B1, prostate cancer mortality and modifiable outcomes
Authors: Pedro F. S. Freitas, Alireza Abdshah, Rana R. McKay
More posts featuring Rana McKay.
Dr. Rana McKay is a board-certified medical oncologist and specializes in urogenital cancers, offering treatment for bladder, kidney, prostate, and testicular cancer patients. Leading a multi-disciplinary prostate cancer clinic at UC San Diego, she ensures comprehensive care through collaboration with urologists and radiation oncologists.
As an associate professor, Dr. McKay mentors students and conducts research on clinical trials and novel biomarkers for genitourinary malignancies. Dr. McKay is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023